Eli Lilly And Cao (NYSE:LLY) announced the results from the VIVID-2 open-label extension study of Omvoh (mirikizumab-mrkz). In January, the FDA approved Omvoh for moderately to severely active Crohn's ...

Mirikizumab-mrkz, an interleukin-23 antagonist ... NCT04232553), an open-label extension study evaluating the long-term effects of the drug. The study population in VIVID-2 included 43.8% of ...

In January 2024, the FDA expanded the drug’s indication list to include Crohn disease. 2 However, studies comparing mirikizumab with other UC medications in the randomized clinical trial (RCT ...

More than 90% of Omvoh-treated patients who were in clinical remission at one year sustained it with two years of continuous treatment Omvoh works to reduce inflammation within the gastrointestinal ...

The FDA granted mirikizumab-mrkz (Omvoh; Eli Lilly) an expanded indication for Crohn disease, meaning the drug can now be used to treat the full spectrum of patients with inflammatory bowel ...

92.9% of patients in clinical remission at one year maintained remission at two years, and 87.6% sustained an endoscopic response. Among those not in clinical remission at one year, 60.8% achieved ...

Eli Lilly has shared positive two-year results from an open-label extension (OLE) study of Omvoh (mirikizumab-mrkz) in active ...

Drug-induced liver injury in conjunction with ... in the Private Securities Litigation Reform Act of 1995) about Omvoh (mirikizumab-mrkz) as a treatment for people with moderate to severe Crohn's ...

In addition, 40% of mirikizumab patients achieved resolution or near resolution of bowel urgency, considered to be one of the most distressing symptoms of UC, said Lilly. The drug performed better ...

The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two ...